The first quarter of 2017 witnessed a surge in Securities Class Action filings. In addition, merger objection litigation continued at a relatively high rate. A significant driver of this has been the prominence of litigation involving companies in the pharmaceutical and biotech industries.
On April 27, a group of panelists to discussed some of the differences between the two industries and the drivers of litigation.
This is a free, one-hour webinar.
The following panelists participated in the webinar: